General
Preferred name
VORINOSTAT
Synonyms
SAHA ()
suberoylanilide hydroxamic acid ()
suberoylanilide hydroxamic acid (SAHA) ()
MK0683 ()
Zolinza ()
Vorinostat (SAHA) ()
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide ()
SKI390 ()
WIN64652 ()
L-001079038 ()
Octanediamide, N-hydroxy-N'-phenyl- ()
SAHA,MK0683, Suberoylanilide hydroxamic acid, Zolinza ()
NSC-701852 ()
MK-0683 ()
NSC-759852 ()
NSC-748799 ()
SAHA-d5 ()
P&D ID
PD001323
CAS
149647-78-9
1227736-21-1
1132749-48-4
Tags
available
nuisance
drug
obsolete probe
covalent binder
Approved by
FDA
First approval
2006
Drug indication
Cutaneous T-cell lymphoma
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Vorinostat inhibits Class I, II and IV histone deacetylases (our pages for HDACs are available using this link). (GtoPdb)
DESCRIPTION inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8 (Informer Set)
DESCRIPTION Thymidylate synthetase inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Class I and II HDAC inhibitor (Tocriscreen Plus)
Cell lines
680
Organisms
11
Compound Sets
40
A Collection of Useful Nuisance Compounds (CONS) for Interrogation of Bioassay Integrity
AdooQ Bioactive Compound Library
A10979
Axon Medchem Screening Library
3114
Cayman Chemical Bioactives
10009929
22107
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
CHEMBL98
ChEMBL Drugs
CHEMBL98
Concise Guide to Pharmacology 2019/20
6852
Concise Guide to Pharmacology 2021/22
6852
Concise Guide to Pharmacology 2023/24
6852
CovalentInDB
CI000012
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB02546
DrugBank Approved Drugs
DB02546
DrugCentral
4124
DrugCentral Approved Drugs
4124
DrugMAP
DMWMPD4
DrugMAP Approved Drugs
DMWMPD4
Enamine BioReference Compounds
Guide to Pharmacology
6852
Informer Set
56554
LINCS compound set
10282-101
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL98
MedChem Express Bioactive Compound Library
HY-10221
NCATS Inxight Approved Drugs
58IFB293JI
NIH Approved Oncology Drugs
48426290
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Obsolete Compounds
vorinostat
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Vorinostat-saha
TargetMol Bioactive Compound Library
T1583
The Spectrum Collection
Tocris Bioactive Compound Library
4652
Tocriscreen Plus
4652
Welcome Trust Cancer Drugs
1012
ZINC Tool Compounds
ZINC000001543873
External IDs
58
Properties
(calculated by RDKit )
Molecular Weight
264.15
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
1
Aromatic Ring Count
1
cLogP
2.47
TPSA
78.43
Fraction CSP3
0.43
Chiral centers
0.0
Largest ring
6.0
QED
0.38
Structural alerts
2
historic compounds (Chemical Probes.org)
Obsolete
Nonspecific HDAC inhibition
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
HDAC inhibitor Class I, IIa, IIb, IV
Histone deacetylase 3
Histone deacetylase 1
Histone deacetylase 2
Histone deacetylase 6
HDAC
HIV
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9
Filovirus
HPV
Mitophagy
Autophagy,HDAC,HPV
Compound status
FDA
Target Type
Enzymes
Pathway
chromain histone acetylation
Chromatin/Epigenetic
DNA Damage/DNA Repair
Anti-infection
Apoptosis
Autophagy
Cell Cycle/DNA Damage
Epigenetics
MOA
histone deacetylase inhibitor
Inhibitor
HDACs
Apoptosis Inducers
Histone Deacetylase 1 (HDAC1) Inhibitors
Histone Deacetylase 2 (HDAC2) Inhibitors
Histone Deacetylase 6 (HDAC6) Inhibitors
Histone Deacetylase 3 (HDAC3) Inhibitors
"HDACs
Inhibitor"
HDAC inhibitor
Primary Target
Non-selective HDACs
Member status
member
Indication
cutaneous T-cell lymphoma (CTCL)
Therapeutic Class
Anticancer Agents
Nuisance MOA
Nonspecific HDAC inhibition
Targets
Histone deacetylases (HDACs) Human papillomaviruse (HPV)-18
Source data